Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Weather and prehospital predictors of trauma patient mortality in a rural American state.
Surg Pract Sci
June 2022
Department of Surgery, Maine Medical Center, 887 Congress Street, Suite 21022 Bramhall St, Portland, ME 04102, USA.
Introduction: In rural settings, factors like weather and location can significantly impact total prehospital time and survival after injury. We sought to determine what prehospital conditions affect mortality and morbidity in severely injured patients.
Materials And Methods: We retrospectively evaluated adult trauma patients that were admitted to our level 1 trauma center with Glasgow Coma Score (GCS≤ 9), hypotension (SBP≤ 90 mmHg), or both.
T cell redirection as a new standard of care for relapsed multiple myeloma: impact on inpatient capacity, financial burden and infrastructural requirements in Germany.
Bone Marrow Transplant
January 2025
Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, University Cancer Center Hamburg-Eppendorf, Hamburg, Germany.
Disease-modifying strategies: Targeting protein kinases in multiple sclerosis and other autoimmune disorders.
Autoimmun Rev
January 2025
Department of Neurology, Hannover Medical School, 30625 Hannover, Germany. Electronic address:
A wide variety of immunomodulatory therapies are already available for the treatment of multiple sclerosis (MS). Through fundamental insights from basic research with a gain of knowledge in the pathological processes underlying MS, the exploration of additional medical compounds within clinical trials has been ignited. Emerging novel medications with innovative mechanisms of action are being introduced.
View Article and Find Full Text PDFThe publication fate of abstracts awarded prizes at European Society of Paediatric Radiology annual scientific meetings.
Pediatr Radiol
January 2025
School of Medicine and Population Health, University of Sheffield, Sheffield, UK.
Background: The European Society of Paediatric Radiology (ESPR) awards prizes for outstanding work presented at their annual scientific meetings. The proportion of ESPR prize-winning abstracts to journal publications is not known. Contextualising abstract-to-publication proportions by evaluating publication experience can yield valuable insights and actionable outcomes to support researchers in overcoming barriers to journal publication.
View Article and Find Full Text PDFRavulizumab demonstrates long-term efficacy, safety and favorable patient survival in patients with paroxysmal nocturnal hemoglobinuria.
Ann Hematol
January 2025
Division of Hematology-Oncology, Hanyang University Seoul Hospital, Seoul, Republic of Korea.
Ravulizumab is a second-generation complement component 5 (C5) inhibitor (C5i) approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) following positive results from two pivotal trials in patients with PNH originally naive to C5i treatment and eculizumab-experienced patients with PNH. In both trials, after the 26week primary evaluation period, all patients received ravulizumab for up to 6 years. To report ravulizumab treatment outcomes in patients with PNH originally naive to C5i treatment and eculizumab-experienced patients with PNH treated for up to 6 years.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!